EU Restricts High-Dose Cyproterone Because of Meningioma Risk EU Restricts High-Dose Cyproterone Because of Meningioma Risk

Products containing the antiandrogen cyproterone with daily doses of 10 mg or more should be restricted because of a risk of meningioma.News Alerts
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news